ArticleTobacco prevention & cessation2026
A Telegram-based behavioral intervention for smoking cessation after myocardial infarction: A study protocol of a pragmatic, single-blind, randomized trial.
Article in Tobacco prevention & cessation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smoking cessation after myocardial infarction (MI) is critical, yet many patients relapse soon after discharge, especially where structured follow-up is limited. Telegram provides a low-cost tool for implementing chatbot-based behavioral support that hospitals can run with minimal technical resources. The aim is to conduct TELEGRAM-MI trial tests to ascertain whether a 6 month Telegram-based chatbot improves cessation outcomes compared with routine discharge advice provided by cardiology staff. This pragmatic, single-blind, randomized trial, starting in 2026 at a regional clinical hospital in Russia, will enroll adult current cigarette smokers hospitalized with acute MI who use Telegram. Participants are randomized 1 : 1 to routine discharge advice plus a passive bot (control) or to the same advice plus an active 6 month behavioral support bot. The intervention includes motivational messages, craving-management tools, an SOS function, weekly check-ins, and relapse-prevention sequences. The primary outcome is 30 day point prevalence abstinence at 6 months, verified by a blinded assessor and a relative. Secondary outcomes include 7 day abstinence at 1 and 3 months, changes in cigarettes/day, nicotine dependence, motivation, engagement, and time to relapse. Analysis will follow intention-to-treat principles. Recruitment begins in January 2026. Results are expected after completion of the 6 month follow-up in October 2026. The intervention could enhance cessation, sustain recovery after MI, and offer a practical way to extend secondary prevention beyond the hospital site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.